C
바이젠셀
308080KOSDAQ44.0 / 100
Reference Date: 2026-10-23
Financial Score17.5 / 40
News Sentiment12.5 / 25
Momentum4.0 / 20
Disclosure10.0 / 15
AI Analysis: the debt ratio is very low with excellent financial health but ROE is below the industry average. Declined 14.2% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
Bizen Cell is a biotech venture company established in 2013, specializing in the development and manufacturing of immunotherapy drugs. Leveraging its HLA research expertise and utilizing umbilical cord blood-derived immune therapies, the company is advancing as a cell therapy specialist through pipelines such as ViTier and ViMedier, while expanding into global new drug development and advanced regenerative medicine.
Number of Employees
43people
Average Salary
86.2M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
—Industry Average 1.203.5Point
ROE
-32.09Industry Average 8.000.0Point
Well below industry avg
Debt Ratio
20.24Industry Average 100.008.0Point
Half of industry avg (excellent)
Trend 2023~20252.0 / 10 points
Revenue Growth Rate
0.0 / 3
Avg ▼91.9% (1-year basis)
Operating Profit Growth Rate
2.0 / 3
Avg ▲6.0% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -25.3% (declining, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (15%, downtrend)
Current 5,070Won52-week high 15,80052-week low 3,090
1-month return1.0Point
1m -14.21% (falling)
Volume trend2.0Point
Volume decreasing
Detailed Disclosure
1 totalPositive 0Neutral 1Negative 0
- Neutral기업설명회(IR)개최2026-10-07